{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-005399","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.058369+00:00","generated_at":"2026-06-06T20:32:40.888384+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sagimet reports positive Phase 2b NASH trial: denifanstat meets primary endpoints with statistical significance","bullets":["NASH resolution without worsening fibrosis (≥2-point NAS reduction): 36% denifanstat vs 13% placebo (p=0.0022).","Fibrosis improvement ≥1 stage without NASH worsening: 41% denifanstat vs 18% placebo (p=0.0051).","MRI-PDFF ≥30% reduction: 65% denifanstat vs 21% placebo (p<0.0001).","No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-005399","json":"https://secwatch.observer/filing/0001104659-24-005399.json","markdown":"https://secwatch.observer/filing/0001104659-24-005399.md","text":"https://secwatch.observer/filing/0001104659-24-005399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924005399/0001104659-24-005399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924005399/tm2333216d8_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:32:40.888384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}